文献速递慢性肾脏病肾小球疾病

改进临床试验入组标准以识别有终末期肾病风险的糖尿病患者

Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease.
PubMed 文献 · Kidney Int · 2017-04-07

该研究利用Joslin肾脏研究自然史数据,在279例1型糖尿病训练队列(3年内134个终点事件)和221例2型糖尿病验证队列(88个终点事件)中开发并验证新的预后标准。基于血清肿瘤坏死因子受体1水平(>4.3 ng/ml,或2.9-4.3 ng/ml且尿白蛋白肌酐比>1900 mg/g)的标准在1型和2型糖尿病中表现相似,总体敏感性和预后价值分别为72%和81%。应用该标准可减少未来临床试验所需样本量。

要点

  • 新标准为血清肿瘤坏死因子受体1>4.3 ng/ml,或2.9-4.3 ng/ml且尿白蛋白肌酐比>1900 mg/g。
  • 该标准在1型和2型糖尿病中结果相似,总体敏感性72%、预后价值81%。
  • 应用该标准入组可减少未来临床试验达到足够统计效能所需样本量。

核心结论

  • 应用基于血清肿瘤坏死因子受体1和尿白蛋白肌酐比的新标准入组未来临床试验,可减少检测治疗获益所需样本量。

研究设计与样本

  • 利用Joslin肾脏研究自然史数据开发改进标准,训练队列为279例1型糖尿病患者(3年内134个终点事件),验证队列为221例2型糖尿病患者(88个终点事件)。
  • 终点事件定义为终末期肾病、估算肾小球滤过率下降40%或死亡。
  • 采用分类与回归树分析从所有临床特征和标志物中选择最佳预后标准。

主要发现

  • 既往试验采用基线尿白蛋白肌酐比和估算肾小球滤过率的临床标准,应用于本队列数据得到的敏感性为70-80%,预后价值仅为52-63%。
  • 最佳标准为血清肿瘤坏死因子受体1水平>4.3 ng/ml,或2.9-4.3 ng/ml且尿白蛋白肌酐比>1900 mg/g。
  • 该标准在1型和2型糖尿病患者中产生相似结果,总体敏感性和预后价值分别为72%和81%。

关键数值与推荐

  • 最佳预后标准:血清肿瘤坏死因子受体1>4.3 ng/ml,或2.9-4.3 ng/ml且尿白蛋白肌酐比>1900 mg/g。
  • 该标准总体敏感性72%,预后价值81%。
  • 既往临床标准敏感性70-80%,预后价值52-63%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Design of Phase III trials for diabetic nephropathy currently requires patients at a high risk of progression defined as within three years of a hard end point (end-stage renal disease, 40% loss of estimated glomerular filtration rate, or death). To improve the design of these trials, we used natural history data from the Joslin Kidney Studies of chronic kidney disease in patients with diabetes to develop an improved criterion to identify such patients. This included a training cohort of 279 patients with type 1 diabetes and 134 end points within three years, and a validation cohort of 221 patients with type 2 diabetes and 88 end points. Previous trials selected patients using clinical criteria for baseline urinary albumin-to-creatinine ratio and estimated glomerular filtration rate. Application of these criteria to our cohort data yielded sensitivities (detection of patients at risk) of 70-80% and prognostic values of only 52-63%. We applied classification and regression trees analysis to select from among all clinical characteristics and markers the optimal prognostic criterion that divided patients with type 1 diabetes according to risk. The optimal criterion was a serum tumor necrosis factor receptor 1 level over 4.3 ng/ml alone or 2.9-4.3 ng/ml with an albumin-to-creatinine ratio over 1900 mg/g. Remarkably, this criterion produced similar results in both type 1 and type 2 diabetic patients. Overall, sensitivity and prognostic value were high (72% and 81%, respectively). Thus, application of this criterion to enrollment in future clinical trials could reduce the sample size required to achieve adequate statistical power for detection of treatment benefits.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Yamanouchi M, Skupien J, Niewczas MA, et al. Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. Kidney Int. 2017. PMID: 28396115. doi:10.1016/j.kint.2017.02.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。